Physician profile
Christopher J Bruce
NPI 1487743027
$16,800.37
in general payments reported to CMS, 2019-2025
20 companies · $4,341 in 2025
The $4,341 reported for 2025 was more than what 87% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $84.14 · 2021: $5,251 · 2022: $792 · 2023: $5,027 · 2024: $960 · 2025: $4,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,027 · Food and Beverage: $2,051 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,026.89 |
| Food and Beverage | $2,051.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,719.88 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $1,620.65 | 2021-2025 | Interstim, Apollotm |
| Thd America, INC. | $423.87 | 2020-2024 | |
| W. L. Gore & Associates, INC. | $308.33 | 2024-2025 | Gore Cardioform Septal Occluder |
| Ethicon US, LLC | $162.22 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $113.40 | 2023 | Rebyota |
| Abbvie INC. | $79.26 | 2024-2025 | |
| Celgene Corporation | $75.62 | 2020-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $53.00 | 2023-2024 | Gattex, Entyvio |
| Bayer Healthcare Pharmaceuticals INC. | $38.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.20 | 2019-2020 | |
| Celltrion USA INC. | $26.89 | 2024 | Zymfentra |
| Integra Lifesciences Corporation | $26.67 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Daiichi Sankyo INC. | $26.51 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $20.58 | 2023 | Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $19.13 | 2021 | |
| Incyte Corporation | $15.95 | 2019 | |
| Lilly USA, LLC | $15.75 | 2019 | |
| Seagen INC. | $14.20 | 2019 | |
| Conmed Corporation | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.